drugset / Trial / NCT01206088
Tasigna in Glivec-resistant or Intolerant Patients in CML
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate efficacy and safety of nilotinib in patients with Imatinib resistant or intolerant CML-CP or AC. Efficacy evaluation will be made by Complete cytogenetic response rate(CCyR) at 12 months after nilotinib administration.
Timeline
- Start
- 2009-02
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nilotinib | Small molecule | — | — |